Roche Reports Eight-Year CLEOPATRA Data for Perjeta in HER2-Positive Breast Cancer

Roche today presented eight-year overall survival data from the Phase 3 CLEOPATRA trial evaluating Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel in patients with previously untreated HER2-positive metastatic breast cancer. The data showed that 37% of patients in the Perjeta arm were alive at eight years compared to 23% in the placebo arm.